Stock Events

CanSino Biologics 

$2.83
1
+$0.11+3.97% Today

Statistics

Day High
2.87
Day Low
2.83
52W High
4.02
52W Low
1.86
Volume
500
Avg. Volume
216
Mkt Cap
278.61M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

23AugConfirmed
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q1 2024
Next
-0.29
0.77
1.82
2.87
Expected EPS
-0.0450092758
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CASBF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BioNTech
BNTX
Mkt Cap23.05B
BioNTech competes directly in the development of mRNA vaccines, similar to CanSino's viral vector COVID-19 vaccine.
Moderna
MRNA
Mkt Cap63.85B
Moderna is a leader in mRNA technology for vaccines, directly competing with CanSino's vaccine development approach.
Astrazeneca
AZN
Mkt Cap243.51B
AstraZeneca developed a viral vector COVID-19 vaccine, similar to CanSino, making them direct competitors in the vaccine market.
Johnson & Johnson
JNJ
Mkt Cap353.71B
Johnson & Johnson also developed a viral vector COVID-19 vaccine, competing in the same space as CanSino.
Pfizer
PFE
Mkt Cap163.65B
Pfizer, in collaboration with BioNTech, competes in the vaccine market, particularly with mRNA technology which is a leading approach in vaccine innovation.
Sinovac Biotech
SVA
Mkt Cap644.66M
Sinovac Biotech is another major Chinese biopharmaceutical company that develops vaccines, competing in the same regional market as CanSino.
Novavax
NVAX
Mkt Cap2.18B
Novavax develops vaccines based on protein subunit technology, offering alternative vaccine options and competing in the global vaccine market.
GSK
GSK
Mkt Cap93.51B
GlaxoSmithKline is a large pharmaceutical company with a broad vaccine portfolio, competing globally with companies like CanSino.
Sanofi
SNY
Mkt Cap122.94B
Sanofi is involved in vaccine development and production, competing in the same market as CanSino with a diverse range of vaccine technologies.
CureVac N.V.
CVAC
Mkt Cap826.12M
CureVac competes in the mRNA vaccine space, offering technologies that could rival CanSino's viral vector vaccine approach.

About

Health Technology
Pharmaceuticals: Major
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
Show more...
CEO
Xuefeng Yu
Employees
1494
Country
CN
ISIN
CNE100003F01
WKN
000A2PGFW

Listings